Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington DC, 78–85 (1994).
  Google Scholar
• 2  Faraone SV, Sergeant J, Gillberg C, Biederman J: The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2, 104–113 (2003).
  MedlineGoogle Scholar
• 3  Wilens TE, Faraone SV, Biederman J: Attention-deficit/hyperactivity disorder in adults. JAMA292, 619–623 (2004).
  Medline CASGoogle Scholar
• 4  Rohde LA, Biederman J, Busnello EA et al.: ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions and impairments. J. Am. Acad. Child Adolesc. Psychiatry38, 716–722 (1999).
  Medline CASGoogle Scholar
• 5  National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J. Am. Acad. Child Adolesc. Psychiatry39, 182–193 (2000).
  MedlineGoogle Scholar
• 6  Castellanos FX, Tannock R: Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci.3, 617–628 (2002).• Extensively discusses the neurobiology of ADHD.
  Medline CASGoogle Scholar
• 7  Faraone SV: Genetics of childhood disorders: XX. ADHD, Part 4: Is ADHD genetically heterogeneous? J. Am. Acad. Child Adolesc. Psychiatry39, 1455–1457 (2000).
  Medline CASGoogle Scholar
• 8  Kirley A, Hawi Z, Daly G et al.: Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology27, 607–619 (2002).
  Medline CASGoogle Scholar
• 9  Banaag C, Bange F, Bouvard M et al.: Consensus statement on ADHD/HKD. Eur. Child Adolesc. Psychiatry (2005) (In press).
  Google Scholar
• 10  Biederman J, Spencer T, Wilens T: Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int. J. Neuropsychopharmacol.7, 77–97 (2004).
  Medline CASGoogle Scholar
• 11  Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J: Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit/hyperactivity disorder. J. Clin. Psychopharmacol.24, 24–29 (2004).
  Medline CASGoogle Scholar
• 12  Spencer T, Heiligenstein J, Biederman J et al.: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry63, 1140–1147 (2002).
  Medline CASGoogle Scholar
• 13  Michelson D, Adler L, Spencer T et al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry53, 112–120 (2003).
  Medline CASGoogle Scholar
• 14  Masellis M, Basile VS, Muglia P, Ozdemir V, Macciardi FM, Kennedy JL: Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention deficit/hyperactivity disorder. Behav. Brain Res.130, 85–90 (2002).
  MedlineGoogle Scholar
• 15  Tribut O, Lessard Y, Reymann JM, Allain H, Bentué-Ferrer D: Pharmacogenomics. Med. Sci. Monit.8, 152–163 (2002).
  MedlineGoogle Scholar
• 16  Rohde LA, Roman T, Hutz M: Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics. Pharmacogenomics J.3, 11–13 (2003).
  Medline CASGoogle Scholar
• 17  Roman T, Rohde LA, Hutz M: Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention-deficit/hyperactivity. Am. J. Pharmacogenomics 4, 83–92 (2004).•  Reviews in detail all studies assessing effects of individual polymorphisms at DAT1 on response to MPH in ADHD.
  Medline CASGoogle Scholar
• 18  Faraone SV, Doyle AE, Mick E, Biederman J: Meta-analysis of the association between the dopamine D4 gene 7-repeated allele and attention-deficit/hyperactive disorder. Am. J. Psychiatry158, 1052–1057 (2001).
  Medline CASGoogle Scholar
• 19  Winsberg BG, Comings DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry 38, 1474–1477 (1999).
  Medline CASGoogle Scholar
• 20  Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics12, 497–499 (2002).••  Describes an association between the 10R allele at DAT1 and response to MPH in a sample of 50 children with ADHD.
  Medline CASGoogle Scholar
• 21  Hamarman S, Ulger C, Fossella J, Brimacombe M, Dermody J: Influence of dopamine genes on stimulant response in ADHD children. Proceedings of the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, USA, 7A (2003).
  Google Scholar
• 22  Kirley A, Lowe N, Hawi Z et al.: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet.121B, 50–54 (2003).
  MedlineGoogle Scholar
• 23  Stein MA, Sarampote C, Waldman I et al.: Dopamine transporter genotype affects stimulants response according to parent ratings. Proceedings of the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, USA, 7C (2002).
  Google Scholar
• 24  Lott DC, Kim SJ, Cook EH, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology30, 602–609 (2004).
  MedlineGoogle Scholar
• 25  Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ: Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol. Psychiatry5, 396–404 (2000).
  Medline CASGoogle Scholar
• 26  Hamarman S, Ulger C, Fossella J, Brimacombe M, Dermody J: Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetics study. J. Child Adolesc. Psychopharmacol.14, 564–574 (2004).••  Reports that individuals with the 7R allele at the DRD4 gene achieved less normalization of symptoms at MPH doses of 50 mg/day and required 1.5-times higher levels of MPH to achieve improvement than those without the 7R allele.
  MedlineGoogle Scholar
• 27  Biederman J, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry46, 1234–1242 (1999).
  Medline CASGoogle Scholar
• 28  Park L, Nigg JT, Waldman ID et al.: Association and linkage of α-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol. Psychiatry (2004) (In press).
  Google Scholar
• 29  Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz M: Further evidence for the association between DBH gene and attention-deficit/hyperactivity disorder. Am. J. Med. Genet.114, 154–158 (2002).
  MedlineGoogle Scholar
• 30  Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz M: Association between α-2a adrenergic receptor gene (ADRA2A) and attention-deficit/hyperactivity disorder. Am. J. Med. Genet. 120B, 116–120 (2003).
  MedlineGoogle Scholar
• 31  Yang L, Wang Y, Li J, Faraone S: Association of norepinephrine transporter gene (NET) with methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry43, 1154–1158 (2004).••  Describes different responses to MPH in hyperactive-impulsive scores according to NET1 G1287A genotypes in a sample of 45 Chinese children with ADHD.
  MedlineGoogle Scholar
• 32  Seeger G, Schloss P, Schmidt MH: Marker gene polymorphisms in hyperkinetic disorder – predictors of clinical response to treatment with methylphenidate? Neurosci. Lett.313, 45–48 (2001).•• The only study that assesses gene–gene interaction in the field of ADHD pharmacogenomics.
  Medline CASGoogle Scholar
• 33  Kent L, Doerry U, Hardy E et al.: Evidence that variation at the serotonin transporter gene influences susceptibility to attention deficit hyperactivity disorder (ADHD): analysis and pooled analysis. Mol. Psychiatry7, 908–912 (2002).
  Medline CASGoogle Scholar
• 34  Van der Meulen E, Bakker SC, Pauls DL, Sinke RJ, Buitelaar J: A genome-wide quantitative trait locus analysis on methylphenidate response rate in Dutch sib pairs with attention-deficit hyperactivity disorder. Proceedings of the 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Berlin, Germany, S-076–351 (2004).
  Google Scholar
• 35  Rohde LA, Roman T, Szobot C, Cunha RD, Biederman J, Hutz MH: Dopamine transporter gene, response to methylphenidate and cerebral blood flow in ADHD. Synapse48, 87–89 (2003).
  Medline CASGoogle Scholar
• 36  Cheon KA, Ryu YH, Kim JW, Cho DY: The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur. Neuropsychopharmacol.15, 95–101 (2005).•• Integrates findings suggesting the association between the 10R allele at DAT1 and poor response to MPH in ADHD in a potentially more comprehensive explanation of the mechanism of action of MPH.
  Medline CASGoogle Scholar
• 37  Swanson JM, Flodman P, Kennedy J et al.: Dopamine genes and ADHD. Neurosci. Biobehav. Rev.24, 21–25 (2000).
  Medline CASGoogle Scholar
• 38  Mill J, Asherson P, Browes C, D'Souza U, Craig I: Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am. J. Med. Genet.114, 975–979 (2002).
  MedlineGoogle Scholar
• 39  Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S: The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J.1, 152–156 (2001).
  Medline CASGoogle Scholar
• 40  Heinz A, Goldman D, Jones DW et al.: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology22, 133–139 (2000).
  Medline CASGoogle Scholar
• 41  Volkow ND, Wang GJ, Fowler JS et al.: Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43, 181–187 (2002).
  Medline CASGoogle Scholar
• 42  Loo SK, Specter E, Smolen A, Hopfer C, Teale PD, Reite ML: Functional effects of the DAT1 polymorphism on EEG measures in ADHD. J. Am. Acad. Child Adolesc. Psychiatry42, 986–993 (2003).
  MedlineGoogle Scholar
• 43  Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM: Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics6, 243–250 (1996).
  Medline CASGoogle Scholar
• 44  Eisenberg J, Mei-Tal G, Steinbeg A et al.: Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention-deficit/hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am. J. Med. Genet.88, 497–502 (1999).
  Medline CASGoogle Scholar
• 45  Barr CL, Wigg K, Malone M et al.: Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am. J. Med. Genet.88, 710–713 (1999).
  Medline CASGoogle Scholar
• 46  Payton A, Holmes J, Barrett JH et al.: Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit/hyperactivity disorder: a family-based study. Am. J. Med. Genet.105, 464–470 (2001).
  Medline CASGoogle Scholar
• 47  Mattay VS, Goldberg TE, Fera F et al.: Catechol O-methyltransferase Val158-Met genotype and individual variation in the brain response to amphetamine. Proc. Natl Acad. Sci. USA100, 6186–6191 (2003).• Reports that amphetamine enhanced the efficiency of prefrontal cortex function assayed with functional MRI during a working memory task in subjects with the high enzyme activity Val/Val genotype, who presumably have relatively less prefrontal synaptic dopamine.
  Medline CASGoogle Scholar
• 48  Volkow ND, Wang GJ, Fowler JS et al.: Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry161, 1173–1180 (2004).••  Provides a new paradigm for the mechanism of action of MPH.
  MedlineGoogle Scholar
• 49  Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics2, 229–243 (2002).
  Google Scholar
• 50  Sauer JM, Ponsler GD, Mattiuz EL et al.: Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 31, 98–107 (2003).
  Medline CASGoogle Scholar
• 51  Faraone SV, Biederman J, Monuteaux MC: Toward guidelines for pedigree selection in genetic studies of attention-deficit/hyperactivity disorder. Genet. Epidemiol.18, 1–16 (2000).
  Medline CASGoogle Scholar
• 52  Lichter JB, Barr CL, Kennedy JL, van Tol HHM, Kidd KK, Livak KJ: A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum. Mol. Genet.2, 767–773 (1993).
  Medline CASGoogle Scholar
• 53  Yeh M, Morley KI, Hall WD: The policy and ethical implications of genetic research on attention deficit hyperactivity disorder. Aust. N. Z. J. Psychiatry38, 10–19 (2004).
  MedlineGoogle Scholar

Websites

• 101  www.ncbi.nlm.nih.gov/entrez/query.fcgi PubMed homepage.
  Google Scholar
• 102  www.apa.org/psycinfo/ PsycINFO homepage.
  Google Scholar
• 103  www.scielo.br The Scientific Electronic Library Online.
  Google Scholar